stijn rogiers

Passionate about HealthCare and Life Sciences. Working at Argenx. Views expressed are my own and do not necessarily reflect those of Argenx.

[KV Mechelen @kvmechelen]

We gingen langs op de pediatrie in ziekenhuizen Imelda & Sint-Maarten en hadden voor elk kindje een verrassing 🎁

Met Hartslag25 zorgden we voor meer dan 50 pakketten om bij zoveel mogelijk kinderen in het ziekenhuis doorbrengen, toch een lach op hun gezicht te toveren 🪄🥰

[KV Mechelen @kvmechelen]

Patrick en Lion vragen het zo lief, die kan je toch niks weigeren 😏

Bekijk het hele knotsgekke interview met onze twee Duitsers binnenkort op YouTube.

Tickets kan je kopen via 👉 https://t.co/TwaY2q8MXl

#trotsoponzekleuren

[argenx @argenxglobal]

How do you build a successful science organization in #biotech? Let’s ask Peter Ulrichts, PhD, argenx Chief Scientific Officer.

#TogetherWeDiscover #leadership #argenx #innovation #collaboration #biotech #biology #immunology

[argenx @argenxglobal]

To the #CIDP community: thank you. Our ADHERE trial wouldn’t have been successful without the efforts of the @gbscidp and the CIDP community. It is because of you that we can potentially bring #immunology innovations to people with #RareDiseases.
#TogetherWeDiscover #NeuroTwitter

[argenx @argenxglobal]

#BreakingNews: We’ve received #FDA approval of the subcutaneous formulation of our FcRn blocker for anti-acetylcholine receptor (AchR) antibody positive generalized myasthenia gravis in adults. Discover more here: https://t.co/oLOLkBzDld

[argenx @argenxglobal]

This past weekend, we demonstrated our continued commitment to the #ITP community at #EHA2023, where Dr. Carpenedo presented interim results of our ADVANCE+ study.

#TogetherWeDiscover #PlateletDisorder #ImmuneThrombocytopenia @EHA_Hematology

[argenx @argenxglobal]

Four #argonauts co-authored a new paper with our industry peers in @frontiersin, exploring the benefits of support systems for people living with #MG – and the reality that many aren’t able to utilize these services.

Discover more here: https://t.co/jryYiXhrJa

#MGAwarenessMonth

[KV Mechelen @kvmechelen]

Grote teleurstelling, nog grotere support 🙏

Met zo'n fans win je alleen. Tot volgend seizoen 💛❤️

#trotsoponzekleuren #wegaanmetznallen

[KV Mechelen @kvmechelen]

Het SPOQ fandorp ontwaakt... 💛❤️

Nog tot 12u45 kan je terecht in het fandorp voor frisse pintjes, merchandise en vooral heel veel sfeer 🥳

📸 An Rogier & Inge Smits

#trotsoponzekleuren #wegaanmetznallen #VoorLei

[argenx @argenxglobal]

What a start to the day at #AANAM! The #argonauts attended the Run/Walk for Brain Research along the Boston waterfront to support key research programs.

Now back to our booth (#2383) to continue meeting leaders in #neuromuscular disorders.

#TogetherWeDiscover #neurology

[argenx @argenxglobal]

This #AutoimmuneAwarenessMonth, we’re raising awareness of some of the biggest challenges facing #RareDisease patients and advocacy groups. First up: the diagnosis odyssey.

#TogetherWeDiscover #AutoimmuneDisease #ChronicIllness

[argenx @argenxglobal]

The resilience of the #RareDisease community has driven Peter Ulrichts, Chief Scientific Officer, and his colleagues since the early days of argenx.

Watch below to discover more about his argenx journey.

#TogetherWeDiscover #BiotechCareers #culture #careers

[argenx @argenxglobal]

#JPM2023 is on, and we’re thrilled to be back. argenx Chief Scientific Officer Peter Ulrichts shares a preview of what to expect.

#TogetherWeDiscover #biotech #JPM2023

[stijn rogiers @StijnRogiers]

@jonathanageneve @jonathanageneve Beautiful !! I’ll come back if you can arrange me a house next to the slopes ;) winter skiing and summer cycling… damn.

[argenx @argenxglobal]

“We are excited to present our ITP data in a plenary session at ASH, giving us the opportunity to highlight the potential of a new approach to treating this rare disease.” - Luc Truyen, M.D., Ph.D., Chief Medical Officer

Learn more: https://t.co/7I4XY0vRWP

#TogetherWeDiscover

[argenx @argenxglobal]

#BreakingNews: We’re pleased to announce the U.S. FDA has accepted the Biologics License Application (BLA) for our FcRn blocker for priority review.

Discover more here: https://t.co/fWv7AmyRWW

#TogetherWeDiscover

[argenx @argenxglobal]

Today, we announced our third-quarter 2022 financial results and provided a business update and outlook for the remainder of the year.

Discover more here: https://t.co/roXrw383xb

#TogetherWeDiscover

[UCI @UCI_cycling]

🌈 REMCO EVENEPOEL 🌈
W O R L D C H A M P I O N

#Wollongong2022

[argenx @argenxglobal]

#BreakingNews Today, we received a positive opinion from the CHMP of the European Medicines Agency on our product for antibody-positive generalized #MyastheniaGravis.

#TogetherWeDiscover

[Anne @AnneData4LS]

How can we make health care more delightful? Join SAS and health care visionary Dr. Koen Kas for an out-of-the-box discussion about improving health care delivery models via #digitaltwins and delight thinking. #TheHealthPulse https://t.co/zqbxT93QkG